Odyssey Therapeutics key facts
as of Oct 2026- Operator of a biotechnology company intended to develop immunomodulators and oncology drugs.
- Odyssey Therapeutics is valued at approximately $638.2M as of Oct 2026, per PrivateMarketView’s mark.
- It has raised $716.2M across 4 recorded rounds; the latest was Later Stage VC ($214.0M) in Jun 2025.
- Notable investors include General Catalyst, Fidelity Management & Research Company, KB Investment, Alexandria Venture Investments, OrbiMed — 32 tracked in total.
- 1 institutional filer reports fund marks on Odyssey Therapeutics across 1 filings.
- Odyssey Therapeutics has filed 5 Form Ds with the SEC since 2021, most recently Dec 2025 ($214.0M sold to 55 investors).
- Status: In IPO Registration.
Reported valuation; nothing comparable since.
- ·The complete investor list: 32 names
- ·Watch Odyssey Therapeutics: the Monday email on marks, rounds and moves
Institutional fund marks on Odyssey Therapeutics
1 filers · latest May 20261 SEC-registered fund reported 1 fair-value mark on Odyssey Therapeutics between May 2026 and May 2026. Filer-level marks and implied $/share are available to Pro members.
Membership and data by Private Market View
Odyssey Therapeutics funding rounds
4 roundsWho backs Odyssey Therapeutics
32+Odyssey Therapeutics valuation
Odyssey Therapeutics is valued at approximately $638 million as of Oct 2026. The figure is set by institutional fund marks.
How much has Odyssey Therapeutics raised?
Odyssey Therapeutics has raised $716 million across 4 recorded rounds since 2021. The largest was a $91.6 million later-stage round in Aug 2021; the most recent was a $214 million later-stage round in Jun 2025.
Odyssey Therapeutics has filed 5 Form Ds with the SEC since 2021, most recently in Dec 2025 ($214 million sold to 55 investors).
Institutional holders and vehicles
1 SEC-registered fund reported 1 fair-value mark on Odyssey Therapeutics for May 2026, in their N-PORT filings. Filer-level marks and implied per-share values are available to Pro members.
Odyssey Therapeutics investors
32 investors are on record for Odyssey Therapeutics, including General Catalyst, Fidelity Management & Research Company, KB Investment and Alexandria Venture Investments. By type, the record holds 9 venture capital firms and 4 hedge funds. The later-stage round in Jun 2025 drew 55 investors.
Comparable companies
Comparable biotechnology names by valuation on PrivateMarketView: Cardurion ($760 million), DNA Script ($660 million) and bit.bio ($546 million).
About Odyssey Therapeutics
Operator of a biotechnology company intended to develop immunomodulators and oncology drugs. The company aims to advance the drug discovery space with its product pipeline and accelerate the path of clinical development, enabling the healthcare industry to get next-generation precision immunomodulators and oncology medicines.
- Industry
- Biotechnology
- Sector
- Healthcare
- HQ
- Boston, MA, United States
- Founded
- 2018
- Employees
- 118
- Website
- odysseytx.com/
- Ownership
- In IPO Registration
Is this your company? Sign in with your work email to keep it current, or tell us what's wrong.